Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.

NCT01466231 is registered in ClinicalTrials.gov with National Cancer Institute, Slovakia as lead sponsor.

NCT NCT01466231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.
Lead sponsor
National Cancer Institute, Slovakia
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
June 30, 2015
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell tumor